Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

US Patent 9610249 · Granted Apr 4, 2017

Estimated economic value: $5,986,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Bi-specific fusion proteins2023
Bi-specific fusion proteins2023
Methods for treating metastatic pancreatic cancer using combination therapies co2022
Therapeutic cell systems and methods for treating cancer and infectious diseases2021
Bi-specific fusion proteins2021
Bi-specific fusion proteins2020
Bi-specific fusion proteins2019
Bi-specific fusion proteins2018
Compositions and methods for non-invasive imaging2018
Compositions and methods for non-invasive imaging2018
Combination therapy for treating HER2-positive cancers2018
Combination therapy for treating HER2-positive cancers2018